We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.67 | -2.38% | 27.49 | 28.49 | 27.40 | 28.31 | 65,588,937 | 00:59:52 |
From May 2019 to May 2024
Indian pharmaceutical company Strides Arcolab Ltd. (532531.BY) said Friday it has expanded its generic drugs supply agreement with Pfizer Inc. (PFE) beyond the U.S. to other developed markets and strengthened the existing drug supply agreement for the U.S. market.
Strides Arcolab will license and supply up to 38 generic cancer drugs to Pfizer for markets in the European Union, Canada, Australia, New Zealand, Japan and Korea, the Indian company said in a statement.
The two companies have signed another agreement covering niche sterile injectable drugs for the U.S. market, the statement added.
The company didn't disclose any financial terms.
-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
